Company: CSTL
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0001628280-25-048254
Chunk: 33

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-11-03
Form: 10-Q
Item: Item 1
Chunk 33
---
, R&D tax credit and state income taxes. For the nine months ended September 30, 2024, differences in our effective rate and the federal statutory rate of 21% was due to stock-based compensation, permanent differences, changes in valuation allowance, R&D tax credit and state income taxes.

15. Segment and Related Information

The Company derives revenues through the delivery of test reports for our molecular diagnostic tests. All of our operations are located within the United States and our business is focused on the U.S. market. We have a single reportable segment consisting of a single operating segment.

25

Table of ContentsCASTLE BIOSCIENCES, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)(UNAUDITED)

The measures of segment (loss) income for of our single reportable segment were as follows (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Net revenues from external customers(1)$83,043 $85,782 $257,219 $245,758 Significant segment expenses:Personnel costs52,863 48,732 156,614 142,699 Organizational and marketing costs11,267 10,271 39,983 33,106 Inventory usage6,127 5,191 16,316 14,991 Clinical studies and publication costs2,183 2,188 6,191 8,002 Professional services2,524 2,559 8,398 8,103 Other segment items8,580 14,572 51,543 30,202 Segment (loss) income$(501)$2,269 $(21,826)$8,655 (1)For information on disaggregation of segment revenue by type and information about payor concentration, see Note 3.Other Segment ItemsOther segment items include all other operating expenses types to included IT service and software licensing costs, fixed and variable expenses incurred for leasing of facilities and equipment, depreciation and amortization, gain or losses on disposal of fixed assets in the routine course of business, fair value adjustment for equity securities, realized gains or losses on investment securities, administrative costs, expense for use of prepaids to include insurance premiums and warranties for lab equipment, public company costs (less audit fees), interest and other non-operating income, and income tax expense or benefits. Our CODM does not individually review budgets or results for